Roche’s Quarterly Sales Drop as Major Drugs Miss Estimates

Roche Holding AG revenue declined last quarter as sales for some of the Swiss drugmaker’s major medicines fell short of analysts’ expectations. The shares slid.

Sales fell 1.4% to 14.9 billion Swiss francs ($18.7 billion), the company said Thursday. Analysts had anticipated about 15.2 billion francs. The blockbuster eye drug Vabysmo, one of Roche’s most important growth drivers, the hemophilia treatment Hemlibra and Ocrevus for multiple sclerosis all fell short of estimates.